Last reviewed · How we verify
LBEC0101
LBEC0101 is a therapeutic candidate in phase 3 development by LG Life Sciences with an undisclosed or proprietary mechanism of action.
At a glance
| Generic name | LBEC0101 |
|---|---|
| Sponsor | LG Life Sciences |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific molecular mechanism of LBEC0101. As a phase 3 investigational drug from LG Life Sciences, detailed mechanistic data may be proprietary or not yet widely published in the scientific literature.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) (PHASE3)
- A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy (PHASE3)
- Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel® (PHASE1)
- Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBEC0101 CI brief — competitive landscape report
- LBEC0101 updates RSS · CI watch RSS
- LG Life Sciences portfolio CI